Tarsus Pharmaceuticals(TARS)
$75.95-2.25 (-2.88%)
TARS
Tarsus Pharmaceuticals financials statements
$75.95
At close:-2.25 (-2.88%)
Want to see TARS full AI Analyst Report?
Tarsus Pharmaceuticals (TARS) Ratios
298 Followers
Tarsus Pharmaceuticals Ratios
TARS's free cash flow for Q3 2026 was $-7.21M. For the 2026 fiscal year, TARS's free cash flow was decreased by $-1.21M and operating cash flow was $-6.00M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 3.85 | 4.42 | 6.93 | 14.61 | 15.33 |
| Quick Ratio | 3.82 | 4.39 | 6.85 | 14.61 | 15.33 |
| Cash Ratio | 1.35 | 1.18 | 6.09 | 4.64 | 14.93 |
| Solvency Ratio | -0.30 | -0.75 | -1.97 | -1.77 | -1.11 |
| Operating Cash Flow Ratio | -0.09 | -1.03 | -3.18 | -3.18 | 0.33 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ 304.05M | $ 204.25M | $ 187.63M | $ 190.41M | $ 163.78M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.17 | 0.19 | 0.11 | 0.09 | 0.01 |
| Debt-to-Equity Ratio | 0.27 | 0.32 | 0.15 | 0.10 | 0.01 |
| Debt-to-Capital Ratio | 0.21 | 0.24 | 0.13 | 0.09 | 0.01 |
| Long-Term Debt-to-Capital Ratio | 0.19 | 0.24 | 0.13 | 0.09 | 0.00 |
| Financial Leverage Ratio | 1.64 | 1.68 | 1.35 | 1.18 | 1.07 |
| Debt Service Coverage Ratio | -6.23 | -14.30 | -40.83 | -28.92 | 0.00 |
| Interest Coverage Ratio | -7.94 | -16.19 | -44.39 | -30.38 | 0.00 |
| Debt to Market Cap | 0.02 | 0.03 | 0.05 | 0.05 | 0.00 |
| Interest Debt Per Share | 2.45 | 2.12 | 1.14 | 0.90 | 0.09 |
| Net Debt to EBITDA | 1.68 | 0.21 | 1.48 | 0.86 | 12.59 |
| Profitability Margins | |||||
| Gross Profit Margin | 93.20% | 92.99% | 90.87% | 96.30% | 96.36% |
| EBIT Margin | -12.28% | -58.87% | -759.71% | -232.53% | -24.15% |
| EBITDA Margin | -11.88% | -58.20% | -754.69% | -231.27% | -23.60% |
| Operating Profit Margin | -15.72% | -65.90% | -820.53% | -242.92% | -21.32% |
| Pretax Profit Margin | -14.26% | -63.16% | -778.89% | -240.53% | -24.15% |
| Net Profit Margin | -14.72% | -63.16% | -778.89% | -240.51% | -24.25% |
| Continuous Operations Profit Margin | -14.72% | -63.16% | -778.89% | -240.51% | -24.25% |
| Net Income Per EBT | 103.20% | 100.00% | 100.00% | 99.99% | 100.40% |
| EBT Per EBIT | 90.69% | 95.84% | 94.93% | 99.02% | 113.28% |
| Return on Assets (ROA) | -11.81% | -30.65% | -51.19% | -27.25% | -7.73% |
| Return on Equity (ROE) | -19.34% | -51.46% | -68.99% | -32.19% | -8.29% |
| Return on Capital Employed (ROCE) | -16.64% | -40.68% | -62.64% | -29.52% | -7.26% |
| Return on Invested Capital (ROIC) | -16.64% | -40.60% | -62.53% | -29.42% | -7.20% |
| Return on Tangible Assets | -11.97% | -31.34% | -51.94% | -27.25% | -7.73% |
| Earnings Yield | -1.94% | -5.55% | -22.84% | -17.20% | -2.99% |
| Efficiency Ratios | |||||
| Receivables Turnover | 5.18 | 3.81 | 0.98 | 7.21 | 619.86 |
| Payables Turnover | 1.87 | 0.46 | 0.09 | 0.17 | 0.73 |
| Inventory Turnover | 7.02 | 4.90 | 0.51 | 0.00 | 0.00 |
| Fixed Asset Turnover | 20.76 | 63.84 | 5.21 | 16.85 | 31.18 |
| Asset Turnover | 0.80 | 0.49 | 0.07 | 0.11 | 0.32 |
| Working Capital Turnover Ratio | 1.36 | 0.74 | 0.08 | 0.14 | 0.35 |
| Cash Conversion Cycle | -72.48 | -618.95 | -2989.57 | -2050.69 | -501.79 |
| Days of Sales Outstanding | 70.44 | 95.88 | 370.59 | 50.64 | 0.59 |
| Days of Inventory Outstanding | 52.01 | 74.56 | 711.90 | 0.00 | 0.00 |
| Days of Payables Outstanding | 194.93 | 789.39 | 4072.05 | 2101.33 | 502.38 |
| Operating Cycle | 122.45 | 170.44 | 1082.48 | 50.64 | 0.59 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.30 | -2.21 | -4.00 | -1.99 | 0.18 |
| Free Cash Flow Per Share | -0.53 | -2.25 | -4.19 | -2.01 | 0.15 |
| Dividend Paid and CapEx Coverage Ratio | -1.26 | -52.98 | -21.35 | -96.90 | 6.40 |
| Capital Expenditure Coverage Ratio | -1.26 | -52.98 | -21.35 | -96.90 | 6.40 |
| Operating Cash Flow Coverage Ratio | -0.13 | -1.15 | -3.89 | -2.43 | 1.98 |
| Operating Cash Flow to Sales Ratio | -0.03 | -0.45 | -6.73 | -1.90 | 0.07 |
| Free Cash Flow Yield | -0.65% | -4.06% | -20.67% | -13.72% | 0.68% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -51.50 | -18.04 | -4.38 | -5.81 | -33.45 |
| Price-to-Sales (P/S) Ratio | 7.58 | 11.38 | 34.10 | 13.98 | 8.11 |
| Price-to-Book (P/B) Ratio | 9.96 | 9.27 | 3.02 | 1.87 | 2.77 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -153.35 | -24.61 | -4.84 | -7.29 | 146.26 |
| Price-to-Operating Cash Flow Ratio | -274.78 | -25.08 | -5.06 | -7.36 | 123.39 |
| Price-to-Earnings Growth (PEG) Ratio | 1.07 | 0.54 | -0.05 | -0.02 | 0.68 |
| Enterprise Value Multiple | -62.14 | -19.34 | -3.04 | -5.18 | -21.77 |
| Enterprise Value | 3.33B | 2.06B | 400.28M | 309.47M | 293.03M |
| EV to EBITDA | -62.14 | -19.34 | -3.04 | -5.18 | -21.77 |
| EV to Sales | 7.38 | 11.26 | 22.94 | 11.99 | 5.14 |
| EV to Free Cash Flow | -149.32 | -24.35 | -3.25 | -6.25 | 92.67 |
| EV to Operating Cash Flow | -267.55 | -24.81 | -3.41 | -6.31 | 78.18 |
| Tangible Book Value Per Share | 8.04 | 5.75 | 6.57 | 7.84 | 8.11 |
| Shareholders’ Equity Per Share | 8.22 | 5.97 | 6.70 | 7.84 | 8.11 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -0.03 | 0.00 | 0.00 | 0.00 | -0.00 |
| Revenue Per Share | 10.80 | 4.87 | 0.59 | 1.05 | 2.77 |
| Net Income Per Share | -1.59 | -3.07 | -4.62 | -2.52 | -0.67 |
| Tax Burden | 1.03 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.16 | 1.07 | 1.03 | 1.03 | 1.00 |
| Research & Development to Revenue | 0.14 | 0.29 | 2.88 | 1.65 | 0.73 |
| SG&A to Revenue | 0.95 | 1.30 | 0.00 | 1.74 | 0.45 |
| Stock-Based Compensation to Revenue | 0.09 | 0.15 | 1.14 | 0.52 | 0.15 |
| Income Quality | 0.19 | 0.72 | 0.86 | 0.79 | -0.27 |
Currency in USD

